Loading...
Market
What will be the next major milestone for REC-994 announced by Recursion Pharmaceuticals ($RXRX) by June 30, 2025?
2
Resolution / Starting Odds
Start of Phase 3 trial • 33%
FDA approval • 33%
Partnership announcement • 33%
Recursion Pharmaceuticals press releases
Story
Recursion Pharmaceuticals ($RXRX) Announces Positive Phase 2 Results for REC-994 in CCM
Sep 3, 2024, 12:08 PM
Recursion Pharmaceuticals ($RXRX) has announced positive Phase 2 topline results for REC-994, a first-in-disease investigational treatment for symptomatic cerebral cavernous malformation (CCM). The drug met its primary endpoint of safety and tolerability. Additionally, magnetic resonance imaging (MRI)-based secondary efficacy endpoints showed a trend towards reduced lesion volume. Despite these promising results, some investors remain cautious about the AI drug discovery developer's future prospects.
View original story
Similar markets
Meets primary endpoint • 25%
Fails primary endpoint • 25%
Mixed results • 25%
Trial not completed by end of 2025 • 25%
Positive outcome with significant efficacy • 25%
Mixed outcome with limited efficacy • 25%
Negative outcome with no efficacy • 25%
Trial terminated early due to safety concerns • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Partnership with a major pharmaceutical company • 25%
Acquisition by a major pharmaceutical company • 25%
Partnership with a tech company • 25%
No partnership or acquisition • 25%
Yes • 50%
No • 50%
More than 3 new drugs • 25%
2-3 new drugs • 25%
1 new drug • 25%
No new drugs • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than $1 billion • 25%
$1 billion to $5 billion • 25%
$5 billion to $10 billion • 25%
More than $10 billion • 25%
Below $2 billion • 25%
$2 billion to $4 billion • 25%
$4 billion to $6 billion • 25%
Above $6 billion • 25%